Global Antimicrobial Peptides Market Research Report 2023-Competitive Analysis, Status and Outlook by Type, Downstream Industry, and Geography, Forecast to 2029

Global Antimicrobial Peptides Market Research Report 2023-Competitive Analysis, Status and Outlook by Type, Downstream Industry, and Geography, Forecast to 2029

Antimicrobial peptides (AMPs), also known as host defense peptides, are short and generally positively charged peptides found in a wide variety of life forms from microorganisms to humans. Most AMPs can kill microbial pathogens directly, whereas others act indirectly by modulating the host defense systems. Antibacterial and Antimicrobial have some different functions, antibacterial only kill bacteria, and antimicrobial kill all microorganisms.

Market Overview:

The latest research study on the global Antimicrobial Peptides market finds that the global Antimicrobial Peptides market reached a value of USD 261.03 million in 2022. It’s expected that the market will achieve USD 755.71 million by 2028, exhibiting a CAGR of 19.38% during the forecast period.

Restricted use of antibiotics will increase market demand for Antimicrobial Peptides

Antimicrobial Peptides have the advantages of rapid sterilization, broad antibacterial spectrum, less toxicity and side effects, and no immunogenicity. Moreover, due to its special bactericidal mechanism, the inhibited or killed pathogenic microorganisms will not produce resistant strains, and the effect of killing bacteria will not be weakened due to drug resistance. Therefore, Antimicrobial Peptides are ideal substitutes for antibiotics. The abuse of antibiotics directly leads to the increasingly serious problem of drug-resistant bacterial infections in the world. Therefore, to curb the abuse of antibiotics, most governments around the world will further strictly control the control of antibiotics. The strict control of antibiotics has spawned scientists' enthusiasm for research on new antimicrobial drugs. Therefore, Antimicrobial Peptides will have broad application prospects.

Potential for development in the field of medicine

With the development of the world economy, the growth of the total population, and the acceleration of aging, the global pharmaceutical market has maintained steady growth in recent years, and R&D investment in the pharmaceutical industry is on the rise. Antimicrobial Peptides are gaining popularity as therapeutics for various diseases. Antimicrobial Peptides are drugs with the potential for development in immunomodulatory and antifungal drugs. Antimicrobial Peptides have significant, broad-spectrum antibacterial and antitumor activities, as well as the ability to accelerate wound healing and enhance immunity, making it possible as a natural medicine to completely replace traditional antibiotics and antitumor drugs. Studies have shown that Antimicrobial Peptides can specifically inhibit the growth of certain target tumor cells while being harmless to normal human cells, which brings greater hope for the development of Antimicrobial Peptides to replace traditional anticancer drugs. In addition, Antimicrobial Peptides have a certain killing effect on a series of viruses with membrane structures such as HIV and herpes virus. Hence, the Antimicrobial Peptides market is expected to grow owing to increasing demand for cancer, and HIV treatment.

Region Overview:

In 2021, the share of the Antimicrobial Peptides market in United States stood at 38.35%.

Company Overview:

Royal DSM N.V, Xellia, Shenzhen Sunsmile Biotechnology Co.,Ltd were the top 3 players in the Antimicrobial Peptides market in 2022, taking up a market share of 15.94% together.

Segmentation Overview:

Recombinant
Get antimicrobial peptides by gene amplification and gene transfer.

Natural

Extracting antimicrobial peptides from animals and plants.

Among different product types, Natural segment is anticipated to contribute the largest market share in 2027.

Application Overview:

By application, the Pharmaceutical segment occupied the biggest share from 2017 to 2022.

Key Companies in the global Antimicrobial Peptides market covered in Chapter 3:

Shenzhen Sunsmile Biotechnology Co.,Ltd Linzhou Sinagri Yingtai Biological Peptide Co., Ltd.
Sigma-Aldrich Corporation
Roche Holding AG
Abeona Therapeutics Inc.
EnBiotix, Inc.
InvivoGen
GenScript Biotech Corporation
Merck & Co., Inc.

In Chapter 4 and Chapter 14.2, on the basis of types, the Antimicrobial Peptides market from 2018 to 2029 is primarily split into:

Recombinant
Natural

In Chapter 5 and Chapter 14.3, on the basis of Downstream Industry, the Antimicrobial Peptides market from 2018 to 2029 covers:

Pharmaceutical
Animal Feed
Food Additive
Agriculture
Cosmetics
Others

Geographically, the detailed analysis of consumption, revenue, market share and growth rate, historic and forecast (2018-2029) of the following regions are covered in Chapter 8 to Chapter 14:

North America (United States, Canada)
Europe (Germany, UK, France, Italy, Spain, Russia, Netherlands, Turkey, Switzerland, Sweden)
Asia Pacific (China, Japan, South Korea, Australia, India, Indonesia, Philippines, Malaysia)
Latin America (Brazil, Mexico, Argentina)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa)